Pancreatic Surgery Practice Questions

Q: Most common complication of a pseudocyst of the pancreas is

Infection. ***Infection*** - **Infection** is the most common and clinically significant complication of a pancreatic pseudocyst, often leading to sepsis and increased mortality. - While other complications can occur, **secondary infection** transforms a sterile pseudocyst into an abscess, requiring urgent intervention. *Rupture into peritoneum* - While possible, **rupture into the peritoneum** (free rupture) is a less frequent complication compared to infection. - This leads to acute peritonitis and is a highly morbid event, but statistically less common than infection. *Haemorrhage* - **Hemorrhage** (bleeding) into a pseudocyst is a serious and potentially life-threatening complication, but it is less common than infection. - It usually results from erosion into adjacent blood vessels, such as the splenic or gastroduodenal arteries. *Rupture into colon* - **Rupture into the colon** or other adjacent organs (like the stomach or duodenum) can occur, but these are less frequent compared to infection. - Such ruptures can lead to internal fistula formation, but infection remains the predominant complication.

Q: The treatment of an annular pancreas is

Duodeno-duodenostomy. ***Duodeno-duodenostomy*** - **Duodeno-duodenostomy** is the preferred bypass procedure for **annular pancreas**, connecting the dilated **proximal duodenum** to the **distal duodenum** beyond the obstruction point. - The **annular pancreatic tissue must never be divided** as the **main pancreatic duct** traverses through it, making this bypass approach the safest option. *Duodenojejunostomy* - While **duodenojejunostomy** can be used as an alternative bypass, it is **not the first-line treatment** for annular pancreas compared to duodeno-duodenostomy. - This procedure bypasses the obstruction by connecting duodenum to jejunum but is considered a **secondary option** when duodeno-duodenostomy is not feasible. *Gastrojejunostomy* - **Gastrojejunostomy** connects the stomach to jejunum and does **not address the duodenal obstruction** caused by the annular pancreas. - This procedure can lead to complications like **bile reflux gastritis** and **marginal ulcers** without resolving the underlying duodenal obstruction. *Gastro-duodenostomy* - **Gastro-duodenostomy** connects the stomach to duodenum and would **not bypass the obstruction** caused by the annular pancreatic tissue. - This procedure is typically used after **gastrectomy** (Billroth I reconstruction) and is inappropriate for treating duodenal obstruction from annular pancreas.

Q: Middle segment pancreatectomy is avoided in which of the following conditions?

Tumors of tail of pancreas. ***Tumors of tail of pancreas*** - Middle segment pancreatectomy involves resection of the central portion of the pancreas, usually sparing the head and tail. Therefore, it is not suitable for **tumors located in the pancreatic tail**. - For tail tumors, a **distal pancreatectomy** is the standard surgical approach, as it allows for complete resection of the tumor with appropriate margins. *Cystadenoma* - These are often located in the body or tail but can occur in the middle segment. If a **cystadenoma** is located in the middle segment, a middle segment pancreatectomy may be an appropriate treatment. - The decision to perform a middle segment pancreatectomy versus another procedure depends on the exact location and size of the cystadenoma, as well as its malignant potential. *Tumors of head of pancreas* - Tumors in the **head of the pancreas** typically involve crucial structures like the bile duct and duodenum. - For these tumors, a **pancreaticoduodenectomy (Whipple procedure)** is the standard and often only curative surgical option. *Tumor of neck of pancreas* - The **neck of the pancreas** is part of the middle segment of the pancreas. - Tumors in this location are amenable to **middle segment pancreatectomy**, as this procedure specifically targets resecting the central portion while preserving surrounding healthy tissue.

Q: A 60-year-old chronic smoker presented with progressive jaundice, pruritus, and clay-colored stools for 2 months, with a history of waxing and waning of jaundice. A CT scan revealed dilated main pancreatic duct and common bile duct. What is the likely diagnosis?

Periampullary carcinoma. ***Periampullary carcinoma*** - The key feature here is **waxing and waning jaundice**, which is a classic presentation of periampullary carcinoma due to the tumor's location at the ampulla of Vater. - **Mechanism**: The friable tumor tissue can undergo necrosis and sloughing, temporarily relieving the obstruction and causing fluctuating jaundice. - Both **dilated common bile duct and pancreatic duct (double duct sign)** are seen because the tumor involves the ampulla where both ducts converge. - **Chronic smoker** is a risk factor for pancreaticobiliary malignancies. - **Painless obstructive jaundice** with pruritus and clay-colored stools indicates extrahepatic biliary obstruction. *Carcinoma head of pancreas* - While this can also cause the **double duct sign** and obstructive jaundice, it typically presents with **steadily progressive jaundice** rather than waxing and waning. - Pancreatic head tumors cause persistent compression of the CBD, leading to continuous obstruction. - The fluctuating pattern is NOT characteristic of pancreatic head carcinoma. *Chronic pancreatitis* - Can cause dilated ducts and obstructive jaundice due to **fibrotic strictures**, but typically presents with **recurrent abdominal pain** and a history of repeated inflammatory episodes. - Pain is a predominant feature, which is absent in this case. - The clinical picture of painless progressive jaundice favors malignancy over inflammatory disease. *Hilar cholangiocarcinoma* - **Klatskin tumor** affects the confluence of hepatic ducts, causing **intrahepatic bile duct dilation** with normal or minimally dilated distal CBD. - **Pancreatic duct dilation would NOT occur** with hilar cholangiocarcinoma. - The presence of both dilated CBD and pancreatic duct rules this out.

Q: What are the indications for surgical intervention in a patient with pancreatic ascites?

Persistent leak from a stented duct. **Persistent leak from a stented duct** - This indicates that **endoscopic drainage** or stenting has failed to resolve the pancreatic duct leak, requiring a more definitive surgical approach. - **Ongoing leakage** despite internal drainage attempts suggests a persistent anatomical disruption that only surgery can effectively repair. *Persistent symptoms despite medical management* - While persistent symptoms warrant further intervention, this option is too broad and does not specifically point to the failure of less invasive procedures like endoscopic stenting. - Symptoms alone, without evidence of a failed specific intervention, might lead to other non-surgical interventions first. *Initial leak from stented duct* - An initial leak is often managed with **endoscopic stent placement** as the primary, less invasive intervention. - Surgical intervention is typically reserved for cases where initial stenting and conservative measures fail. *Recurrent ascites after drainage with ongoing symptoms* - **Recurrent ascites** after simple drainage (paracentesis) only suggests a persistent leak, but this option does not mention the failure of a stented duct. - The next step after drainage would likely be **endoscopic retrograde cholangiopancreatography (ERCP)** and stenting before considering surgery.

Q: What is the most appropriate treatment plan for a patient diagnosed with a benign insulinoma?

Enucleation. ***Enucleation*** - For **benign solitary insulinomas**, surgical **enucleation** (removal of the tumor while preserving the healthy pancreatic tissue) is the treatment of choice, offering a high cure rate. - This minimally invasive approach minimizes morbidity compared to more extensive pancreatic resections, especially for tumors located superficially or within the pancreatic head. *Enucleation with radiotherapy* - While **enucleation** is the primary treatment for benign insulinomas, **radiotherapy** is generally not indicated as an adjuvant therapy for these benign lesions. - Radiotherapy is more commonly considered for **malignant or unresectable pancreatic neuroendocrine tumors** or for palliative control of symptoms. *Whipple's operation* - A **Whipple's operation (pancreaticoduodenectomy)** is a major surgical procedure typically reserved for tumors in the head of the pancreas that are **malignant or complex**, or for larger benign tumors that cannot be safely enucleated. - For a benign insulinoma that can be enucleated, a Whipple's operation is **overly aggressive** given its high risk of complications and mortality. *Administration of streptozotocin* - **Streptozotocin** is an **antineoplastic agent** that targets pancreatic beta cells and is primarily used for **malignant, metastatic, or unresectable insulinomas** to control symptoms and tumor growth. - It is not an appropriate first-line treatment for a **benign, resectable insulinoma**, as surgical removal is curative.

Q: What is the median survival time for patients with carcinoma of the pancreas after surgery and adjuvant therapy?

Approximately 22 months. ***Approximately 22 months*** - The median survival for patients with **resectable pancreatic adenocarcinoma** treated with surgery (typically pancreaticoduodenectomy) and adjuvant chemotherapy is approximately **22-28 months** based on contemporary studies. - The 22-month figure represents a well-established median from multiple clinical trials including **ESPAC-1 and CONKO-001**, making it the most representative answer among the options provided. - This outcome reflects significant improvement from the pre-adjuvant therapy era but still underscores the aggressive biology of pancreatic cancer. *Approximately 12 months* - This figure represents **historical median survival** prior to the routine use of effective adjuvant chemotherapy, or survival in patients with **unresectable locally advanced disease** treated with palliative chemotherapy alone. - It is **not representative** of outcomes in patients who undergo complete surgical resection followed by modern adjuvant therapy. *Approximately 32 months* - While highly selected patients with **favorable tumor biology** (small tumors, negative margins, low CA 19-9) and optimal response to modern regimens like **FOLFIRINOX** may approach this survival, it exceeds the **median survival** for the general population of resected patients. - This represents the upper quartile rather than the median outcome. *Approximately 44 months* - This exceptionally long survival is **not achieved** as a median in pancreatic ductal adenocarcinoma, even with optimal surgical resection and adjuvant therapy. - Such prolonged survival is occasionally seen in **highly selected patients** or with less aggressive pancreatic neoplasms (e.g., neuroendocrine tumors, intraductal papillary mucinous neoplasms with invasive component), which have substantially better prognoses than typical ductal adenocarcinoma.

Q: Which of the following is the LEAST likely indication for surgical intervention in pancreatic ascites?

Persistent symptoms despite conservative management. ***Persistent symptoms despite conservative management*** - This is the **LEAST likely indication** because it is vague and non-specific compared to the other options - Conservative management for pancreatic ascites (including bowel rest, TPN, somatostatin analogues) typically requires **4-6 weeks to assess efficacy** - "Persistent symptoms" alone does not constitute a surgical indication unless accompanied by **specific complications** or **documented failure** of conservative therapy - Surgery is considered only after clear evidence of treatment failure, not merely symptom persistence during the trial period *Recurrent ascites with significant symptoms* - **Recurrence of ascites** after initial control indicates failure of conservative or endoscopic management - Significant symptoms (abdominal distension, pain, respiratory compromise, malnutrition) with recurrence are a **strong indication for surgical intervention** - Suggests underlying pancreatic duct disruption that requires definitive surgical repair *Failure of medical management* - **Clear failure of medical management** is a **primary indication for surgery** in pancreatic ascites - Includes failure to control ascites with octreotide, TPN, repeated paracentesis, and bowel rest - Indicates need for surgical approaches such as internal drainage, resection, or duct repair *Leak from the stented duct* - A **leak from a stented pancreatic duct** represents **failure of endoscopic therapy** - This is a **direct and specific indication** for surgical intervention - Ongoing pancreatic fluid leakage despite stenting requires surgical repair to prevent complications such as infection, malnutrition, and persistent fluid collections

Question 1

Most common complication of a pseudocyst of the pancreas is

Accepted Answer

Infection

Answer

Rupture into peritoneum

Answer

Haemorrhage

Answer

Rupture into colon

Question 2

The treatment of an annular pancreas is

Accepted Answer

Duodeno-duodenostomy

Answer

Duodenojejunostomy

Answer

Gastrojejunostomy

Answer

Gastro-duodenostomy

Question 3

Middle segment pancreatectomy is avoided in which of the following conditions?

Accepted Answer

Tumors of tail of pancreas

Answer

Tumors of head of pancreas

Answer

Cystadenoma

Answer

Tumor of neck of pancreas

Question 4

A 60-year-old chronic smoker presented with progressive jaundice, pruritus, and clay-colored stools for 2 months, with a history of waxing and waning of jaundice. A CT scan revealed dilated main pancreatic duct and common bile duct. What is the likely diagnosis?

Accepted Answer

Periampullary carcinoma

Answer

Chronic pancreatitis

Answer

Carcinoma head of pancreas

Answer

Hilar cholangiocarcinoma

Question 5

What are the indications for surgical intervention in a patient with pancreatic ascites?

Accepted Answer

Persistent leak from a stented duct

Answer

Initial leak from stented duct

Answer

Persistent symptoms despite medical management

Answer

Recurrent ascites after drainage with ongoing symptoms

Question 6

What is the most appropriate treatment plan for a patient diagnosed with a benign insulinoma?

Accepted Answer

Enucleation

Answer

Enucleation with radiotherapy

Answer

Whipple's operation

Answer

Administration of streptozotocin

Question 7

What is the median survival time for patients with carcinoma of the pancreas after surgery and adjuvant therapy?

Accepted Answer

Approximately 22 months

Answer

Approximately 12 months

Answer

Approximately 32 months

Answer

Approximately 44 months

Question 8

Which of the following is the LEAST likely indication for surgical intervention in pancreatic ascites?

Accepted Answer

Persistent symptoms despite conservative management

Answer

Recurrent ascites with significant symptoms

Answer

Failure of medical management

Answer

Leak from the stented duct

Pancreatic Surgery — MCQs

Pancreatic Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?